About the Rome IV Criteria for Opioid-Induced Constipation
The same six symptom items as functional constipation, hung on a different hook. Rome IV requires new or worsening constipation when initiating, changing or increasing opioid therapy, together with two or more of: straining, hard or lumpy stools, incomplete evacuation, anorectal obstruction, manual manoeuvres — each in more than a quarter of defecations — or fewer than three spontaneous bowel movements a week, plus loose stools rarely present without laxatives. Notably there is **no** three-month or six-month timing requirement: the temporal link to the opioid replaces it.
Formula
OIC = new/worsening constipation on starting, changing or increasing an opioid AND (≥ 2 of 6 symptom items) AND loose stools rare without laxatives- Opioid trigger
- Initiating, changing or increasing therapy. A stable long-term dose with stable constipation sits awkwardly here, and Rome IV does not resolve that case cleanly.
- ≥ 2 of 6
- Identical items and threshold to functional constipation.
- There is NO 3-month or 6-month timing rule in these criteria, unlike almost every other Rome IV disorder. The temporal link to the opioid does that work.
- Rome IV asks that research studies not diagnose functional constipation in patients meeting OIC criteria, while acknowledging the two overlap clinically.
- Opioid effects on the gut do not develop tolerance the way sedation and nausea do — this persists for the duration of therapy.
- The criteria say nothing about opioid dose or duration, only about the temporal relationship.
Interpreting the result
Meeting the criteria should prompt three things. First, prescribe a laxative — and ideally have done so prophylactically at the point the opioid was started, which is the standard of care and frequently omitted. Osmotic and stimulant laxatives are first-line. Second, where laxatives fail, move to a peripherally acting mu-opioid receptor antagonist rather than escalating laxatives further; these target the mechanism directly and do not cross the blood-brain barrier, so analgesia is preserved. Third, and most easily forgotten, ask whether the opioid is still needed and at that dose — treating the consequence while never revisiting the cause is common in long-term opioid prescribing. Where the criteria are not met because there is no temporal link to the opioid, the diagnosis is functional constipation, which uses the same six items but carries the usual Rome IV timing rule and a different set of licensed treatments.
| Score | Band | What it means | Action |
|---|---|---|---|
| Opioid trigger + ≥ 2 items | Opioid-induced constipation | Constipation attributable to opioid therapy, which will persist for as long as the opioid does | Laxative first-line; peripherally acting mu-opioid receptor antagonist if that fails; review whether the opioid is still needed |
| No opioid trigger | Criteria not met | Constipation not linked to starting, changing or increasing an opioid | Assess for functional constipation, which uses the same six symptom items |
| Fewer than 2 items | Criteria not met | Below the symptom threshold | Still worth prophylactic laxative if an opioid has just been started — the criteria describe established constipation, not risk |
What the Opioid-Induced Constipation needs (8 inputs)
- New or worsening constipation on initiating, changing or increasing opioid therapy
- The defining criterion, and the one that replaces the usual Rome IV timing rule. Constipation that predates the opioid and is unchanged by it does not meet this.
- Straining in more than 25% of defecations
- One of six items, two of which are required.
- Lumpy or hard stools (Bristol 1–2) in more than 25% of defecations
- Bristol types 1 and 2 specifically.
- Sensation of incomplete evacuation in more than 25% of defecations
- Opioids act on the enteric nervous system throughout the gut, including the anorectum, so evacuation symptoms are common here rather than incidental.
- Sensation of anorectal obstruction or blockage in more than 25% of defecations
- As above — opioid effects are not confined to transit.
- Manual manoeuvres in more than 25% of defecations
- Digital evacuation or pelvic floor support. Ask directly; it is not volunteered.
- Fewer than three spontaneous bowel movements per week
- Spontaneous means without laxatives.
- Loose stools rarely present without laxatives
- The same exclusion as functional constipation, separating this from a mixed pattern.
What it returns
- Criteria met or not met
- Requires the opioid trigger, two or more symptom items, and the loose-stool exclusion.
- Number of symptom items met
- Reported out of six.
How it is calculated
Opioids act on mu-opioid receptors in the enteric nervous system, reducing propulsive motility, increasing non-propulsive segmental contraction, raising sphincter tone and increasing fluid absorption. The result is slower transit, harder stool and impaired evacuation simultaneously, which is why the symptom profile spans both transit and evacuation items rather than being purely one or the other. Crucially, the enteric receptors do not down-regulate in the way central receptors do, so tolerance does not develop — a patient stable on an opioid for years remains as constipated as they were at the start. Rome IV's decision to define the disorder by its temporal relationship to the drug rather than by a duration follows from that pharmacology: the constipation begins when the opioid does and continues while it continues, so a three-month rule would add nothing except delay.
Facts & figures
| Feature | Implication |
|---|---|
| No tolerance develops | Unlike sedation and nausea, this persists for the whole duration of therapy |
| Acts throughout the gut, including the anorectum | Produces both transit and evacuation symptoms, not one or the other |
| Predictable at prescription | Justifies prophylactic laxative rather than reactive treatment |
| Reversible without losing analgesia | Peripherally acting mu-opioid receptor antagonists do not cross into the CNS |
| A common reason for stopping analgesia | Untreated, it undermines the pain management it accompanies |
The absence of tolerance is the single most useful fact to convey to a patient who assumes, reasonably, that this will settle as their other opioid side effects did.
Evidence
Derivation — Rome Foundation, bowel disorders committee
2016Consensus criteria from the Rome IV bowel disorders committee, published in Gastroenterology in 2016. Opioid-induced constipation was given its own criteria for the first time in Rome IV.
Consensus-derived. The distinctive structural choice is the absence of a duration requirement — the temporal relationship to the opioid replaces the three-month and six-month rules used across the rest of Rome IV.
Guideline adoption — AGA 2019
2019American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation.
Sets out laxatives as first-line and recommends peripherally acting mu-opioid receptor antagonists for patients with an inadequate response, on evidence that they improve bowel function without reversing analgesia.
Related guidance — AGA/ACG chronic idiopathic constipation 2023
2023Joint AGA and ACG guideline on the pharmacological management of chronic idiopathic constipation.
Provides the evidence base for the laxative and secretagogue options used first-line in this population, though its primary target is non-opioid constipation.
How it compares
Opioid-Induced Constipation vs Functional constipation
Identical symptom items, different trigger and no duration rule — and Rome IV asks research studies to keep them apart while conceding they overlap in practice.
Both use the same six items with the same two-item threshold and the same loose-stool exclusion. Functional constipation adds the three-month and six-month timing rules and requires that IBS criteria are not met; opioid-induced constipation drops the timing rules entirely and requires a temporal link to starting, changing or increasing an opioid. Clinically the distinction matters because peripherally acting mu-opioid receptor antagonists are licensed for one and not the other. Rome IV's own footnote acknowledges that in a patient on long-term opioids with other reasons to be constipated, the separation is difficult.
Opioid-Induced Constipation vs Narcotic bowel syndrome
Different opioid complication entirely — one is constipation, the other is opioid-induced worsening of abdominal pain, and they can coexist.
Opioid-induced constipation is a peripheral motility effect. Narcotic bowel syndrome is a hyperalgesic state in which the opioid amplifies the abdominal pain it is being given for, marked by pain that worsens as doses escalate and a 'soar and crash' pattern as doses wane. The treatments diverge completely: opioid-induced constipation is managed alongside continued opioid therapy, while narcotic bowel syndrome requires opioid withdrawal. A patient on long-term opioids with both constipation and escalating abdominal pain may well have both, and the pain component is the one that will not improve until the opioid is stopped.
Opioid-Induced Constipation vs Functional defecation disorders
Opioids impair evacuation as well as transit, so a patient can have both — and the evacuation component will not respond to opioid antagonists alone.
Because opioids raise anal sphincter tone and impair rectoanal coordination, evacuation symptoms are part of the expected picture rather than a sign of a separate problem. But where incomplete evacuation and manual manoeuvres dominate and persist despite adequate treatment of the constipation, anorectal physiology testing is worth doing — a coexisting functional defecation disorder responds to biofeedback and to nothing in the opioid-constipation armamentarium. Rome IV requires functional constipation or IBS-C as the prerequisite for that diagnosis, which is a technical wrinkle in a patient whose label is opioid-induced constipation.
Pearls & pitfalls
- There is no three-month rule here. Unlike every other Rome IV disorder, the temporal link to the opioid replaces the duration requirement — so the diagnosis can and should be made early.
- Opioid gut effects do not develop tolerance. Patients reasonably assume this will settle as their nausea and drowsiness did, and it will not.
- Prescribe a laxative when you prescribe the opioid, not when the patient complains. This is standard practice and routinely omitted.
- Where laxatives fail, peripherally acting mu-opioid receptor antagonists are the targeted option and preserve analgesia — escalating laxatives further is the commoner but weaker move.
- Constipation predating the opioid and unchanged by it is functional constipation, not this.
- The criteria say nothing about dose or duration of opioid — only about the temporal relationship to a change in therapy.
- Ask about manual manoeuvres. Opioids affect the anorectum as well as transit, so evacuation symptoms are common and are not evidence against the diagnosis.
- Revisit whether the opioid is still indicated. Treating the constipation indefinitely without ever re-examining the prescription is a recognised failure mode of long-term opioid care.
- A patient stable on a long-term unchanged opioid dose sits awkwardly in these criteria, which are written around initiating or escalating therapy — Rome IV does not resolve that case cleanly.
Critical actions
- Prescribe a laxative prophylactically whenever an opioid is started or increased.
- Establish the temporal relationship explicitly — did the constipation begin or worsen with the opioid?
- Use an osmotic or stimulant laxative first-line and titrate before concluding it has failed.
- Move to a peripherally acting mu-opioid receptor antagonist for inadequate response rather than adding further laxatives.
- Review the analgesic plan — dose reduction, opioid rotation or a non-opioid strategy addresses the cause rather than the consequence.
- Ask about incomplete evacuation and manual manoeuvres, which opioids cause as well as slow transit.
- Exclude impaction, particularly in older or immobile patients, before escalating oral treatment.
- Warn the patient that this side effect will not wear off, so they do not stop treatment expecting it to.
Why this score exists
Giving opioid-induced constipation its own Rome IV criteria was a recognition that it had become common enough, and distinct enough in its treatment, to need naming. The structural decision that stands out is dropping the duration requirement. Every other disorder in Rome IV carries a three-month rule with six-month onset, and the committee removed it here because the causal relationship is direct and immediate — waiting three months to name a drug effect that begins within days would delay treatment for no diagnostic gain. The accompanying footnote is unusually candid: for research purposes patients meeting these criteria should not also be diagnosed with functional constipation, because separating opioid effects from other causes is genuinely difficult, but clinicians are told plainly that the two may overlap. That is a rare acknowledgement in a criteria document that the clean boundary exists for the trials rather than for the clinic.
About the creator
First author, Rome IV bowel disorders committee
Chaired the committee that produced the Rome IV bowel disorder criteria, including the first dedicated criteria for opioid-induced constipation.
Co-author, Rome IV bowel disorders committee
Co-authored the bowel disorders chapter and the subsequent AGA/ACG constipation guideline.
Limitations
- The absence of a duration requirement, while pragmatic, leaves a patient on a stable long-term unchanged opioid dose poorly covered by criteria written around initiation and escalation.
- The boundary with functional constipation is acknowledged as blurred in Rome IV's own footnote, and in practice most long-term opioid users have multiple contributors to constipation.
- Says nothing about opioid dose, duration or type, though these plainly affect severity.
- The symptom items are proportions of defecations, which patients estimate unreliably without a diary.
- Consensus-based, and the temporal attribution to the opioid is a clinical judgement that no study has shown to be reliable between assessors.
- Does not address the impaired evacuation component specifically, despite opioids affecting the anorectum directly.
- Says nothing about severity or about the impact on adherence to analgesia, which is the main clinical consequence.
- Offers no guidance on when opioid reduction should be preferred to treating the constipation.
If you are the patient
Opioid-induced constipation is constipation caused by strong painkillers such as morphine, oxycodone, codeine or tramadol. It is very common, and there is one thing about it that is genuinely important to know: unlike the drowsiness and nausea that often settle after the first week or two, this side effect does not wear off. It lasts for as long as you are taking the medicine, because opioids slow the bowel directly and the bowel does not adapt to them the way the brain does. That is why your doctor should give you a laxative at the same time as the painkiller rather than waiting for a problem — and if that was not done, it is entirely reasonable to ask for one. If ordinary laxatives are not enough, there is a specific group of medicines designed for exactly this situation. They block the opioid's effect on the bowel without blocking its effect on pain, so your pain relief is not affected. Ask about them if laxatives alone are not working, because they are frequently not offered. Finally, it is always worth reviewing with your doctor whether you still need the opioid, or the same dose of it — treating the constipation is helpful, but reducing the cause is better where that is possible.
Frequently asked questions
What are the Rome IV criteria for opioid-induced constipation?#
New or worsening symptoms of constipation when initiating, changing or increasing opioid therapy, including two or more of: straining, lumpy or hard stools, incomplete evacuation, anorectal obstruction, or manual manoeuvres — each in more than 25% of defecations — or fewer than three spontaneous bowel movements per week; plus loose stools rarely present without laxatives.
Is there a duration requirement for opioid-induced constipation?#
No, and this is unusual. Almost every Rome IV disorder requires criteria fulfilled for three months with onset at least six months earlier; opioid-induced constipation has neither. The temporal relationship to starting, changing or increasing the opioid does that work, which means the diagnosis can and should be made early rather than after months of symptoms.
Does opioid-induced constipation get better over time?#
No. Unlike sedation and nausea, the gut effects of opioids do not develop tolerance — the enteric receptors do not down-regulate the way central ones do. A patient stable on an opioid for years remains as constipated as they were at the start. Patients frequently assume it will settle, and telling them otherwise changes whether they stay on effective analgesia.
How is opioid-induced constipation different from functional constipation?#
The symptom items are identical. The difference is the trigger — a temporal link to starting, changing or increasing an opioid — and the absence of a duration rule. Clinically it matters because peripherally acting mu-opioid receptor antagonists are licensed for opioid-induced constipation and target its mechanism directly. Rome IV asks research studies to keep the two apart while acknowledging they overlap in practice.
What treats opioid-induced constipation when laxatives fail?#
Peripherally acting mu-opioid receptor antagonists. They block opioid effects on the enteric nervous system without crossing the blood-brain barrier, so bowel function improves while analgesia is preserved. The AGA guideline recommends them for patients with an inadequate response to laxatives, and they are frequently not offered because the constipation is treated as generic rather than opioid-specific.
Should a laxative be started before constipation appears?#
Yes. Because opioid-induced constipation is predictable, affects a large proportion of patients and does not resolve with time, prophylactic laxative prescription at the point the opioid is started is standard practice. It is one of the more consistently omitted steps in analgesic prescribing.
Can you have opioid-induced constipation and narcotic bowel syndrome together?#
Yes, and it is worth recognising because the management conflicts. Opioid-induced constipation is treated alongside continued opioid therapy; narcotic bowel syndrome — where the opioid amplifies abdominal pain, worsening as doses escalate — requires opioid withdrawal. A patient with both will not have their pain component improve until the opioid is stopped, however well the constipation is managed.
Do the criteria apply to someone on a long-term unchanged opioid dose?#
Awkwardly. The criteria are written around initiating, changing or increasing therapy, so a patient stable on the same dose for years with stable constipation is not cleanly covered. In practice the diagnosis is still made and treated the same way; this is a genuine gap in how the criteria are worded rather than a clinical distinction.
References
Original / primary reference
Clinical practice guidelines
- Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156(1):218-226.
- Chang L, Chey WD, Imdad A, et al. AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023;164(7):1086-1106.